Real-World Outcome and Prognostic Factors of Pazopanib in Advanced Soft Tissue Sarcoma

PURPOSE: Pazopanib has been approved for treating soft tissue sarcomas (STS) after chemotherapy. We aimed to evaluate the prognostic factors, clinical outcomes, and tolerability of pazopanib in patients with STS. PATIENTS AND METHODS: Forty-five patients treated between June 2015 and August 2019 wer...

Descripción completa

Detalles Bibliográficos
Autores principales: Alshamsan, Bader, Badran, Ahmad, Alshibany, Aisha, Maraiki, Fatma, Elshenawy, Mahmoud A, Elhassan, Tusneem, Atallah, Jean Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8414075/
https://www.ncbi.nlm.nih.gov/pubmed/34512015
http://dx.doi.org/10.2147/CMAR.S323499

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8414075/
https://www.ncbi.nlm.nih.gov/pubmed/34512015
http://dx.doi.org/10.2147/CMAR.S323499

Ejemplares similares